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Abstract
Background: CXC chemokine receptor 2 (CXCR2) has been reported to play an important role in the proliferation
and invasion of gastric cancer cells. The present study aims to investigate the impact of CXCR2 expression on the
overall survival (OS) of gastric cancer patients after radical resection.
Methods: Intratumoral CXCR2 expression was evaluated with immunohistochemistry on tissue microarrays
containing tumor samples of 357 gastric cancer patients from a single center. CXCR2 expression levels were
correlated to clinicopathological variables and OS.
Results: CXCR2 expression was mainly located in the cytoplasm of gastric carcinoma cells. High CXCR2 expression was
associated with poor tumor differentiation (p = 0.021), increased tumor depth (p < 0.001), lymph node metastasis
(p < 0.001), advanced TNM stage (p < 0.001) and short OS (p = 0.001). CXCR2 expression was an independent
prognostic factor for OS (p = 0.001) in multivariate analysis, and could be combined with TNM stage to generate
a predictive nomogram for clinical outcome in patients with gastric cancer.
Conclusion: Intratumoral CXCR2 expression is a novel independent predictor for survival in gastric cancer
patients. CXCR2 might be a promising therapeutic target of postoperative adjuvant treatment.
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Background
Despite the incidence of gastric cancer has declined in
the modern society for decades, it remains the fourth
most common malignancy and the third leading cause
of cancer related death worldwide with an estimated
951,600 new cases and 723,100 deaths occurring in
2012 [1]. A substantial proportion of gastric cancer pa-
tients are diagnosed at advanced stages, due to occult
symptoms at early stages, whereas patients in Japan
gain a 5-year overall survival as high as 76 %, attribut-
ing to the screening for early stage gastric cancer [2].
Currently, prognostic models for gastric cancer are
mainly based on the TNM classification of International
Union Against Cancer, composed of tumor depth,
lymph node metastasis and distant metastasis. The
outcomes for patients with similar pathological TNM
stage can be very diverse because of the heterogeneity
of this disease [3, 4]. Therefore, stratifying patients in
the current TNM stage system by incorporation of
the molecules involved in carcinogenesis of gastric
cancer may lead to more accurate prediction of the
clinical outcome.
Chemokines are a superfamily of small molecule
proteins and selectively regulate the recruitment and
activation of leukocyte subsets to preferential sites
through chemotaxis [5]. CXCR2 is a member of the G-
protein-coupled receptor superfamily and the receptor
for chemokines with the presence or absence of ELR
motif (Glu-Leu-Arg). The ELR positive CXC chemo-
kines (such as CXCL1, CXCL2, CXCL3, CXCL5,
CXCL6, CXCL8 and CXCL7) are potent promoters of
angiogenesis [6, 7]. A number of studies have demon-
strated that CXCR2 plays a pivotal role in tumor
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angiogenesis, proliferation and invasion [8–10]. In gastric
cancer, CXCR2 was found to be associated with tumor
progression and invasion [11, 12]. Thus, we hypothesized
that the addition of CXCR2 to TNM staging system has
the potential to provide more individualized risk stratifica-
tion based on molecular characteristics of the tumor.
In this study, we investigated CXCR2 expression in pa-
tients with gastric cancer by immunohistochemistry and
explored its associations with clinicopathological factors
and prognosis. Moreover, we generated a predictive nomo-
gram integrating CXCR2 expression, tumor depth, and
lymph node metastasis to assess the risk score for 5-year
overall survival (OS) of gastric cancer patients.
Methods
Patients
We retrospectively recruited 357 consecutive gastric can-
cer patients from Zhongshan Hospital, Fudan University.
Gastrectomy plus standard D2 lymphadenectomy was
performed by the same surgical team in 2008. None of
these patients received any preoperative chemotherapy or
radiotherapy. Baseline clinicopathological features of these
patients including age, gender, tumor location, tumor size,
tumor differentiation, Lauren classification, and TNM
stage were collected. Tumor stage and differentiation
grade were reassessed according to the 7th Edition of the
UICC/AJCC TNM Staging System by two independent
gastroenterological pathologists. Median age at surgery
was 59 years (range 27–85), and 70 % of patients were
male. Intestinal and diffuse histologic subtypes consti-
tuted 63 % and 37 % of cases, respectively. Lymph node
metastasis was present in 64 % of patients. Patients
were followed up until April 2014 with a median
follow-up time of 41 months. Overall survival was
defined as the interval between the date of surgery and
the date of death or last visit. The study was approved by
the Clinical Research Ethics Committee of Zhongshan
Hospital, Fudan University and written informed consent
was obtained from each patient.
Tissue microarray, immunohistochemical staining and
evaluation
Tissue microarray construction and immunohistochemis-
try protocol were described previously [13]. The primary
antibody against human CXCR2 (Abcam, Cambridge, MA,
USA; dilution 1:100) was applied in the procedure. The
staining intensity and extent were scored independently by
two gastroenterological pathologists (Z. Shen and H.
Zhang) who were blind to the patients’ outcome using the
semi-quantitative immunoreactivity scoring (IRS) system
as described previously [14]. The immunohistochemical-
stained sections were scanned at × 200 magnification and
three independent microscopic fields with the strongest
staining were captured by NIS-Element F3.2 software to
guarantee representativeness and homogeneity. The stain-
ing intensity was graded as 0 (negative), 1 (weak), 2 (mod-
erate), and 3 (strong) and the staining extent was scored as
the percentage of positive cells (0–100 %). The staining
intensity and extent were multiplied to obtain a CXCR2
immunohistochemical score on a scale of 0 to 300. The
agreement among the two pathologists was excellent,
which was evaluated by the kappa value (0.85). To
dichotomize CXCR2 expression into high and low groups,
the score of 200 was selected as the cutoff point according
to the minimum p-value method based on its correlation
with OS. The negative control staining was treated equally
with the primary antibody excluded.
Statistical analysis
SPSS 21.0 (SPSS Inc., IL, Chicago, USA) was used to
perform the analyses. Correlations between immunohisto-
chemical variables and clinicopathologic characteristics
were analyzed with Pearson χ2 and Student’s t tests.
Kaplan-Meier method with log-rank test was applied to
compare survival curves. Cox regression models were used
to analyze the impact of prognostic factors on OS. Nomo-
gram was constructed by R software version 3.0.2 with
“rms” package (R Foundation for Statistical Computing,
Vienna, Austria). Calibration plot for 5-year overall survival
was generated to assess the performance characteristics of
the constructed nomogram. The Harrell’s concordance
indices (c-indices) were calculated to evaluate the discrim-
ination of different models for OS prediction. All statistical
analyses were two-sided and p < 0.05 was regarded as statis-
tically significant.
Results
CXCR2 expression and associations with
clinicopathological features in gastric cancer patients
Immunohistochemical staining section analysis demon-
strated that CXCR2 expression was mainly located in
the cytoplasm of gastric carcinoma cells (Fig. 1b–d). The
median intratumoral CXCR2 staining score was 210
(range 0–300). The negative control showed no staining
neither in gastric epithelial cells nor in stroma cells
(Fig. 1a). The relationships between clinical pathological
characteristics and CXCR2 expression are shown in
Table 1. High CXCR2 expression correlated with poor
tumor differentiation (p = 0.021), increased tumor depth
(p < 0.001), lymph node metastasis (p < 0.001) and ad-
vanced TNM stage (p < 0.001).
High expression of CXCR2 is associated with poor clinical
outcome
The Kaplan-Meier curves revealed that high CXCR2 ex-
pression correlated with shorter OS (p < 0.001, Fig. 2a).
The median survival time for CXCR2 high and low ex-
pression group was 32 and 51 months, respectively.
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Subgroup analysis revealed that intratumoral CXCR2
expression played an unfavorable prognostic role in
patients of T3 (p = 0.001, Fig. 2e), T4 (p = 0.005, Fig. 2f),
N0 (p = 0.003, Fig. 3a), moderate differentiation (p = 0.019,
Fig. 2c), poor differentiation (p < 0.001, Fig. 2d), TNM I +
II (p = 0.002, Fig. 3c), TNM III + IV (p = 0.008, Fig. 3d),
Lauren intestinal type (p < 0.01, Additional file 1: Figure
S1E) and Lauren diffuse type (p = 0.012, Additional file 1:
Figure S1F). In contrast, intratumoral CXCR2 expression
had limited ability to stratify patients with T1, T2, N1, N2,
N3 and well differentiated disease. (Figure 2b, Additional
file 1: Figure S1A-D). To further elucidate the predictive
value of CXCR2 precisely, we calculated its hazard ratios
(HR) using univariate COX regression in different sub-
groups and found that CXCR2 expression exerted the
same adverse prognostic role as it did in Log-rank test
(Additional file 2: Figure S2).
Multivariate analysis and predictive nomogram for OS of
gastric cancer patients
We then evaluated the independent prognostic value of
CXCR2 expression using multivariate Cox proportional
hazard model. The results showed that the CXCR2
expression was independently prognostic of mortality
(HR = 1.860; 95 % CI = 1.343-2.575; p < 0.001) in patients
with gastric cancer after adjusting for established clinico-
pathologic factors (Fig. 4a).
Predictive nomogram was constructed using all the
significant independent predictors for OS from Cox re-
gression analysis. In the nomogram, the hazard ratio for
each factor was turned into points, and a higher total
points indicated worse survival overall probability
(Fig. 4b). The calibration curve for predicted 5-year OS
showed a good performance with the ideal model
(Fig. 4c). The Harrell’s concordance index (c-index) for
the nomogram constructed by TNM and CXCR2 ex-
pression was 0.664, higher than 0.642 of TNM alone.
Discussion
CXCR2 expression has been implicated in gastric can-
cer progression [11, 12, 15, 16]. Coexpression of
CXCL1 and CXCR2 acts like an autocrine or paracrine
mechanism to actuate metastasis of gastric cancer [15].
However, its prognostic value in gastric cancer patients
has not been well established. In this study, we investi-
gated the expression of this chemokine receptor with
Fig. 1 Expression of CXCR2 in sections of gastric cancer. Representative photographs of CXCR2 expression (a–d). Negative control a.
Representative photographs of weak, moderate and strong staining (b–d). Original magnification: ×200
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immunohistochemistry on gastric cancer tissue micro-
array and its relationships with pathologic factors and
prognosis. Our data showed a consistent result with
previous studies that CXCR2 expression positively cor-
related with tumor depth, lymph node metastasis and
TNM stage (Table 1), which implied that CXCR2 ex-
pression might synergize gastric cancer proliferation,
invasion and metastasis.
Notably, an interesting phenomenon had been observed
that CXCR2 staining increased gradually accompanied with
gastric cancer differentiation from well to poor (Fig. 1b–d).
This raised the possibility that CXCR2 expression increases
during the dedifferentiation process of gastric cancer cells
and might take on a particular role in gastric cancer differ-
entiation. However, the biological mechanisms underlying
this phenomenon merit further investigation.
The connection between inflammation and cancer was
first noted by Virchwood in the 19th century [13]. Chronic
inflammation is frequently present before several types of
carcinogenesis. Chemokines are the key molecule for
Table 1 Relation between intratumoral CXCR2 expression and clinical characteristics in patients with gastric cancer (n = 357)
Factor Patients CXCR2 expression
No. % Low High P value
All patients 357 100 157 200
Age (years) 0.250
Mean ± SD† 59.4 ± 11.6 58.6 ± 11.1 60.1 ± 11.9
Gender 0.477
Female 107 30 44 63
Male 250 70 113 137
Tumor size (cm) 0.931
Mean ± SD† 3.8 ± 2.1 3.8 ± 2.4 3.8 ± 1.9
Differentiation 0.021
Well 20 5.6 14 6
Moderately 127 35.6 60 67
Poorly 210 58.8 83 127
Lauren classification 0.910
Intestinal 224 62.7 98 126
Diffuse 133 37.3 59 74
pT stage <0.001
T1 60 16.8 40 20
T2 50 14.0 25 25
T3 65 18.2 27 38
T4 182 51.0 65 117
pN stage <0.001
N0 128 35.8 72 56
N1 37 10.4 21 16
N2 70 19.6 24 46
N3 122 34.2 40 82
Distant metastasis 0.735
Absent 349 97.8 153 196
Present 8 2.2 4 4
TNM stage 0.001
I 78 21.8 49 29
II 80 22.5 37 43
III 191 53.5 67 124
IV 8 2.2 4 4
*p < 0.05 was regarded as statistically significant. †SD: standard deviation
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Fig. 2 Kaplan–Meier analysis for OS of patients with gastric cancer according to the CXCR2 expression. a All patients, n = 357, p < 0.001. b Well
differentiated tumors, n = 20, p = 0.181. c Moderately differentiated tumors, n = 127, p = 0.019. d Poorly differentiated tumors, n = 210, p < 0.001.
e Tumors of T3 stage, n = 65, p = 0.001. f Tumors of T4 stage, n = 182, p = 0.005. p value was calculated by Log-rank test
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inducing leukocytes to inflammation or tumor site [17–
19]. Expression of pro-inflammatory chemokines facili-
tates a chronic inflammation process and helps establish a
favorable tumor milieu, which stimulates tumor prolifera-
tion and invasion via their receptors on tumor cells [20,
21]. Many studies have identified that ELR positive che-
mokines play a pleiotropic role in inflammation, angiogen-
esis, carcinogenesis and metastasis [22–24].
CXCR2 was reported to play a critical role in a range of
cancers, such as colon cancer [25], oral squamous cell
cancer [26], esophageal cancer [27] and breast cancer [28].
CXCR2 had been found to be the primary functional che-
mokine receptor in mediating endothelial cell chemotaxis
[29]. All ELR+ CXC chemokine ligands, binding to
CXCR2, mediated angiogenic activity, which was crucial
for cancer cells proliferation [22]. Heidemann found that
after activation of CXCR2 using interleukin-8 (IL-8),
endothelial cells gained enhanced capacity of fiber
assembly, proliferation and phosphorylation of its down-
stream signaling molecule ERK1/2 while this phenomenon
could be impaired by either using specific antibodies to
CXCR2 or inhibitor for ERK1/2 [24, 25]. The importance
of CXCR2 in angiogenesis in vivo had also been proven in
the cornea micropocket assay by CXCR2 knockout mice
[22]. Thus, the correlation between aberrant expression of
CXCR2 and the poor prognosis of the patients was
possibly due to its angiogenic role in gastric cancer.
Although several biomarkers have been introduced
to the prognosis models for gastric cancer recently
[30,31], conventional predictive models majorly rely
on TNM stage, which has limited ability to discrimin-
ate a stratum of patients for the heterogeneity of this
disease. Kaplan-Meier and univariate COX stratifica-
tion analysis revealed that CXCR2 had a discriminatory
power in most subgroups of different clinicopathological
types (Additional file 2: Figure S2). Further analysis of
Fig. 3 Kaplan–Meier analysis to assess prognostic value of CXCR2 in N0, N1 stage and different TNM stage. a Patients with N0 stage tumor,
n = 128, p = 0.003. b Patients with N1 stage tumor, n = 37, p = 0.060. c Patients with TNM I + II stage tumor, n = 158, p = 0.002. d Patients with
TNM III + IV stage tumor, n = 199, p = 0.008. p value was calculated by Log-rank test
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multivariate COX regression verified that CXCR2 bears
an independent prognostic value, which could be inte-
grated to the TNM staging system in the nomogram
(Fig. 4a–c). Validation test using calibration plot and c-
index indicated that this nomogram performed better
than the TNM stage alone.
Giving the prognostic value of CXCR2 expression in gas-
tric cancer, optimal use of CXCR2 inhibitors would be a
potential choice of adjuvant therapy for gastric cancer pa-
tients after gastrectomy. However, due to the retrospective
design in nature and the relatively small size of the patient
population, a multicenter, prospective study is needed to
validate these results in a larger population in the future.
Conclusion
Our present study identified that intratumoral CXCR2
expression correlates with gastric cancer progression,
tumor differentiation and lymph node metastasis and
can be utilized as a novel prognostic factor for patient
outcomes. Incorporating CXCR2 expression into TNM
stage can provide a better prognostic model for patients
with gastric cancer. Inhibition of CXCR2 might be a
promising target of postoperative adjuvant therapy mo-
dality for gastric cancer patients.
Additional files
Additional file 1: Figure S1. Kaplan–Meier analysis to assess prognostic
value of CXCR2 in some clinicopathological factors. (A) T1 stage, n = 80,
p = 0.386. (B) T2 stage, n = 50, p = 0.803. (C) N2 stage, n = 70, p = 0.124.
(D) N3 stage, n = 122, p = 0.162. (E) Lauren intestinal type, n = 224, p < 0.01.
(F) Lauren diffuse type, n = 133, p = 0.012. (JPEG 322 kb)
Additional file 2: Figure S2. COX analysis assesses prognostic value of
CXCR2 with hazard ratios for OS in subgroups. T3 (n = 65, HR: 3.326, 95 %
CI: 1.522-7.267, p = 0.003), T4 (n = 182, HR: 1.768, 95 % CI: 1.178-2.652,
p = 0.006), N0 (n = 128, HR: 2.782, 95 % CI: 1.389-5.574, p = 0.004),
TNM I + II (n = 158, HR: 2.713, 95 % CI: 1.404-5.241, p = 0.003), TNM III + IV
(n = 199,HR: 1.623, 95 % CI: 1.126-2.340, p = 0.01), well and moderate
differentiation (n = 147, HR: 2.159, 95 % CI: 1.262-3.691, p = 0.005),
poor differentiation (n = 210, HR: 2.158, 95 % CI: 1.448-3.217, p < 0.001),
Fig. 4 Multivariate analysis, nomogram and calibration plot for the predictive value of CXCR2 expression in patients of gastric cancer. a Multivariate
Cox analysis identified independent prognosticators for OS of the cohort. b Nomogram constructed to predict 5-years overall survival in gastric cancer:
Tumor invasion depth (early = T1 + T2, advanced = T3 + T4), Lymph node metastasis (absent = N0, present = N1 + N2 + N3), Distant metastasis
(absent = M0, present = M1) and CXCR2 expression (low = low expression, high = high expression) were included. c Calibration plot for
nomogram-predicted and observed 5-year survival. The nomogram performed well with the ideal model
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Lauren intestinal type (n = 224, HR: 2.573, 95 % CI: 1.672-3.958, p < 0.001),
Lauren diffuse type (n = 133, HR: 1.834, 95 % CI: 1.137-2.960, p = 0.014).
(JPEG 302 kb)
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